乳腺癌已成為全球最常見的癌癥，人表皮生長(zhǎng)因子受體2（HER2）陽性乳腺癌惡性程度較高，早期易復(fù)發(fā)和轉(zhuǎn)移，總體預(yù)后較差。HER2陽性乳腺癌的治療因靶向藥物的不斷問世而呈現(xiàn)更多可能，這類藥物包括單克隆抗體（曲妥珠單抗、帕妥珠單抗）、酪氨酸激酶抑制劑（奈拉替尼、拉帕替尼、吡咯替尼、圖卡替尼）、抗體藥物偶聯(lián)物（T-DM1、DS-8201）。對(duì)HER2陽性乳腺癌靶向治療藥物的最新臨床試驗(yàn)結(jié)果進(jìn)行綜述，以期為該類乳腺癌的臨床用藥提供參考。

Breast cancer has become the most common cancer in the world. Among them, human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly malignant, easy to relapse and metastasize in the early stage and the overall prognosis is poor. With the advent of targeted drugs, more possibilities have been provided for the treatment of HER2-positive breast cancer. These drugs include monoclonal antibodies (trastuzumab, pertuzumab), tyrosine kinase inhibitors (neratinib, lapatinib, pyrotinib and tucatinib), antibody drug conjugates (T-DM1, DS-8201). This article aims to review the latest clinical trial results of targeted therapy drugs for HER2-positive breast cancer, in order to provide a reference for future clinical medication.

R979.1;R984

國(guó)家自然基金青年科學(xué)基金資助項(xiàng)目（81302841）；遼寧省高等學(xué)校優(yōu)秀人才支持計(jì)劃資助項(xiàng)目（LJQ2014086）